Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.
Then David, who leads the Factor XI clinical program at Regeneron, will present preclinical data as well as clinical data from the ROXI-VTE-I and II studies in venous thromboembolism prevention post ...
An easy-to-follow overview of weekly options and how a beginning trader can get up to speed enough to trade weeklies ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
The general mood among these heavyweight investors is divided, with 22% leaning bullish and 59% bearish. Among these notable ...
Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of DirectorsNext-generation GABA-aminotransferase (GABA-AT) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback